Marea Therapeutics Enrolls First Patient in Phase 2b TYDAL-TIMI 78 Clinical Study Evaluating MAR001 in Adults at Risk of ASCVD
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-gener...
What potential regulatory pathway (e.g., FDA accelerated approval, cardiovascular outcome trial) does Marea anticipate for MAR001 if Phase 2b data are positive?
How might the results of TYDAL‑TIMI 78 position MAR001 for advancement into a Phase 3 program, and what timelines are expected for that transition?
What safety signals have emerged in Phase 1 or early Phase 2 data, and how might they influence investor sentiment?
21 days ago